drugset / Trial / NCT07290894
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
NaSingle-groupOpen-labelTreatment
Summary
MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer. 80 patients will be overall enrolled in the study.Three cohorts are planned
Timeline
- Start
- 2026-03-12
- Primary completion
- 2031-10
- Completion
- 2031-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |